Tyra Biosciences, Inc. (TYRA)
Largest Insider Buys in Sector
TYRA Stock Price History Chart
TYRA Stock Performance
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company …
Insider Activity of Tyra Biosciences, Inc.
Over the last 12 months, insiders at Tyra Biosciences, Inc. have bought $19.99M and sold $11.6M worth of Tyra Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Tyra Biosciences, Inc. have bought $46.63M and sold $12.05M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $595.08M. Fuhrman Alan (Chief Financial Officer) — $151,954.
The last purchase of 1,220,681 shares for transaction amount of $19.84M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑11‑08.
List of Insider Buy and Sell Transactions, Tyra Biosciences, Inc.
| 2024-11-25 | Sale | director | 5,272 0.0108% | $16.84 | $88,773 | -4.20% | ||
| 2024-11-08 | 1.22M 2.3305% | $16.25 | $19.84M | -2.54% | ||||
| 2024-11-07 | Sale | director | 22,091 0.0422% | $17.32 | $382,574 | -8.34% | ||
| 2024-11-06 | Sale | director | 52,491 0.1004% | $17.18 | $901,559 | -8.15% | ||
| 2024-11-05 | Sale | director | 10,493 0.0203% | $16.77 | $175,950 | 0.00% | ||
| 2024-11-04 | Sale | director | 1,076 0.0021% | $17.01 | $18,298 | -4.20% | ||
| 2024-11-01 | Sale | director | 27,493 0.0527% | $16.56 | $455,272 | -4.00% | ||
| 2024-10-31 | Sale | director | 100,140 0.1874% | $16.46 | $1.65M | -5.64% | ||
| 2024-10-30 | Sale | director | 11,078 0.0213% | $16.17 | $179,120 | -1.16% | ||
| 2024-10-30 | Chief Financial Officer | 9,500 0.018% | $16.00 | $151,954 | -1.16% | |||
| 2024-10-21 | Sale | President and CEO | 19,084 0.0356% | $27.90 | $532,451 | -44.15% | ||
| 2024-10-18 | Sale | President and CEO | 43,636 0.0818% | $27.01 | $1.18M | -41.97% | ||
| 2024-10-17 | Sale | President and CEO | 15,394 0.029% | $25.85 | $397,872 | -38.93% | ||
| 2024-10-16 | Sale | President and CEO | 33,297 0.0706% | $26.17 | $871,430 | -38.73% | ||
| 2024-10-15 | Sale | President and CEO | 10,035 0.0198% | $24.31 | $243,970 | -34.98% | ||
| 2024-09-30 | Sale | President and CEO | 500 0.001% | $24.00 | $12,000 | -31.18% | ||
| 2024-09-25 | Sale | President and CEO | 600 0.0012% | $24.01 | $14,406 | -2.54% | ||
| 2024-09-24 | Sale | President and CEO | 1,055 0.002% | $24.02 | $25,341 | -2.58% | ||
| 2024-09-23 | Sale | President and CEO | 10,092 0.0195% | $24.13 | $243,477 | -31.35% | ||
| 2024-09-20 | Sale | President and CEO | 7,109 0.0134% | $24.19 | $171,950 | -33.37% |
Insider Historical Profitability
| RA CAPITAL MANAGEMENT, L.P. | 8697956 16.451% | $14.00 | 2 | 0 | <0.0001% | |
| Fuhrman Alan | Chief Financial Officer | 12849 0.0243% | $14.00 | 1 | 0 | |
| Boxer Capital, LLC | 10 percent owner | 6448359 12.1962% | $14.00 | 2 | 0 | <0.0001% |
| MORE ROBERT J | director | 4080296 7.7173% | $14.00 | 1 | 0 | <0.0001% |
| Alta Partners NextGen Fund II Management, LLC | 10 percent owner | 4080296 7.7173% | $14.00 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $170.83M | 19.83 | 10.42M | +43.95% | +$52.15M | 0.17 | |
| Boxer Capital, LLC | $105.75M | 12.27 | 6.45M | 0% | +$0 | 2.17 | |
| Bvf Inc Il | $76.44M | 8.87 | 4.66M | +70.14% | +$31.51M | 0.56 | |
| Canaan Partners Xi Llc | $72.32M | 8.39 | 4.41M | 0% | +$0 | 79.77 | |
| Nextech Invest | $66.52M | 7.72 | 4.06M | +61.04% | +$25.21M | 10.85 |